Anca-L. Grosu, MD gave a talk on the opportunities of GenAI in #cancer at the #WEF24 in #Davos . AI is a driving force to innovate the fight against cancer 🚀🌍
Deutsche Gesellschaft für Radioonkologie e.V. ESTRO Uniklinik Freiburg

Relive the highlights and cutting-edge insights from #EMUC23 focusing on:
✅ Multidisciplinary medical care & research
✅ Key sessions on prostate, urothelial & kidney cancers
✅ Game-changing updates on therapies & groundbreaking trials
👉Read the report: bit.ly/3TpVYU6

Circulating tumor DNA to guide #radonc
❓ Beyond status of “promising biomarker” - ready for prime time

Virtual Grand Rounds in Radiation Oncology
Dr. Andreas Rimner
Dec 6th 17:00 – 17:30 CET

Zoom Link 👇
usz.ch/veranstaltung/…

Endorsed by Deutsche Gesellschaft für Radioonkologie e.V. ESTRO SASRO

Honoured and proud to represent young ESTRO at the #EMUC23 congress in the EAU Young Academics session and present our research (published in IJROBP - The Red Journal, redjournal.org/article/S0360-…). Congratulations to the educational and scientific work done by the European Association of Urology (EAU) colleagues Juan Gómez Rivas 🙌

People ask about our work to why adjuvant ADT more important than neoadjuvant (or even concurrent)...here you go!

Long overdue and big thanks to Steve Allen and Chao Zhang who worked in my lab UMich Rad Onc to get this paper out. Not easy to get a lab paper out when you leave an…

Offering post RP salvage RT to patients with BR & -ve PSMA PET remains an open question.

Our multicenter retrospective study demonstrates favorable bRFS after SRT in PSMA PET -ve patients.

Simon Spohn Nina Schmidt-Hegemann Constantinos Zamboglou Matthias Guckenberger

link.springer.com/article/10.100…

I am very honoured to receive this award. Tremendous team effort by Anca-L. Grosu, MD Constantinos Zamboglou, our medical physicist team and the whole clinical trials unit Radiation Oncology University Freiburg!Thanks to ARO Krebsgesellschaft
#radonc Deutsche Gesellschaft für Radioonkologie e.V.

Drinks with the best 🤩

#ESTRO2023 started great🙌 SRS/SBRT pre-course, fantastic sessions and #young ESTRO mentoring class!
+ meeting old and new friends

Happy to be part of this great consortium and initiative
Andreas Charalambous European Cancer Organisation

🔘PSMA-PET outperforms conventional imaging for initial staging of intermediate-high-risk #prostatecancer according to a meta-analysis of 31 studies.
🔘PSMA-PET was more sensitive for the detection of EPE, SV invasion, N staging, and bone met staging.
European Urology OncoAlert…

36.25 Gy/5 fx linac-based prostate SBRT with 32.5 Gy urethra-sparing delivered every-other-day or once-a-week.
Minimal impact on tox and QoL regardless of OTT: 5-yr G2+ GU and GI tox-free survival ~76% and ~90%; 5-yr bRFS >90% redjournal.org/article/S0360-…

Happy to be part of the 50th Erlanger Training for #Radonc . Fantastic speakers highlighting development and innovations of our great discipline. Kudos for continuing this initiative for half a decade 🙌. Thanks to the wohle Team Uniklinikum Erlangen FAU Erlangen-Nbg Deutsche Gesellschaft für Radioonkologie e.V.

The latest publication from our division of radiobiology delivers new insights into the immunogenic effect of Cisplatin
➡️Cisplatin enhanced the absopcal effect more stronlgy than oxaliplatin or carboplatin
➡️Cisplatin induces antitumour immunity through necroptosis-mediated ICD